SB 204990

Research use only, not for human use.

SB 204990 is an effective and specific ATP citrate lyase enzyme inhibitor.

SB 204990 is an effective and specific ATP citrate lyase enzyme inhibitor.

SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels.

SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels.

——

Endocrinology/Hormones

ATPase

ACLY

——

——

154566-12-8

389.27

C18H22Cl2O5

>98% (HPLC)

DMSO:100 mg/mL (256.89 mM);H2O:10 mg/mL (25.69 mM; Need ultrasonic)

O[C@](CC(O)=O)(C[C@@H](CCCCCCc(ccc(Cl)c1)c1Cl)O1)C1=O

——

(-20℃)

With Ice Pack

≥ 2 years